文献速递妇科产科

浆液性和透明细胞子宫内膜癌辅助治疗的国家治疗模式与癌症特异性结局

National patterns of care and cancer-specific outcomes of adjuvant treatment in patients with serous and clear cell endometrial carcinoma.
PubMed 文献 · Gynecol Oncol · 2018-12-12

本研究基于SEER-Medicare数据库,纳入1789例FIGO I-III期浆液性或透明细胞子宫内膜癌患者,分析辅助放疗、近距离放疗和化疗与癌症特异性死亡的关系。结果提示近距离放疗对I-II期患者生存有益,化疗对III期患者有益,而I-II期浆液性癌同时接受化疗和近距离放疗者4年癌症特异性死亡率最低。

要点

  • I-II期浆液性或透明细胞癌患者中,近距离放疗与更低的癌症特异性死亡相关(UVA P=0.03,MVA P=0.02)。
  • III期患者中,化疗与更低的癌症特异性死亡相关(UVA P=0.002,MVA P=0.006)。
  • I-II期浆液性癌接受近距离放疗和化疗者4年癌症特异性死亡率为9%,低于仅接受一种治疗者(15%)和未接受两者者(25%)。

核心结论

  • 结果表明近距离放疗对I-II期浆液性或透明细胞癌有益,化疗对III期浆液性或透明细胞癌有益,化疗和近距离放疗对I-II期浆液性癌均有益。

研究设计与样本

  • 基于SEER-Medicare数据库的回顾性队列研究,纳入FIGO I-III期浆液性或透明细胞子宫癌且至少接受全子宫切除术的患者1789例(浆液性1437例,透明细胞352例)。

主要发现

  • I-II期患者(n=1188)中,近距离放疗在单因素分析(P=0.03)和多因素分析(P=0.02)中均与生存显著相关。
  • I-II期浆液性癌亚组(n=947)中,化疗在单因素分析中显著(P=0.002),在多因素分析中接近显著(P=0.05)。
  • I-II期浆液性癌的4年癌症特异性死亡率为:未接受近距离放疗和化疗者25%,接受其中一种者15%,接受两者者9%(所有两两比较P≤0.05)。
  • III期患者(n=601)中,化疗在单因素分析(P=0.002)和多因素分析(P=0.006)中均显著。
  • 大多数(81%)患者接受了淋巴结清扫,其与III期患者更低的癌症特异性死亡相关(P=0.001),但在I-II期患者中无此关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate outcomes of adjuvant therapy for serous and clear cell endometrial carcinoma, as prior studies are limited by sample size and/or patient heterogeneity. National guidelines permit substantial variations in treatment, suggesting the need for additional data. METHODS: Patients with FIGO stages I-III serous or clear cell uterine carcinoma who underwent at least total hysterectomy were identified in SEER-Medicare. Adjuvant external beam radiation, brachytherapy, and chemotherapy were determined using SEER fields and Medicare claims. The primary outcome was death from endometrial cancer (cancer-specific mortality [CSM]) evaluated using Gray's test (univariable analysis, UVA) and Fine-Gray regression (multivariable analysis, MVA). RESULTS: A total of 1789 patients (1437 serous, 352 clear cell) were identified. In stages I-II patients (n = 1188), brachytherapy was significant for survival in UVA (P = 0.03) and MVA (P = 0.02). Additionally, in the subset with serous histology (n = 947), chemotherapy was also significant in UVA (P = 0.002) and approached significance in MVA (P = 0.05). The 4-year CSM for stages I-II serous cancers was 25% without brachytherapy or chemotherapy, 15% with one, and 9% with both (P ≤ 0.05 for all pairwise comparisons). In stage III patients (n = 601), chemotherapy was significant in UVA (P = 0.002) and MVA (P = 0.006). Most (81%) patients underwent lymph node dissection, which predicted lower CSM in stage III (P = 0.001) but not stages I-II patients. CONCLUSIONS: Our results suggest brachytherapy benefits stages I-II serous/clear cell cancers, chemotherapy benefits stage III serous/clear cell cancers, and both chemotherapy and brachytherapy benefit stages I-II serous cancers.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Xiang M, English DP, Kidd EA, et al. National patterns of care and cancer-specific outcomes of adjuvant treatment in patients with serous and clear cell endometrial carcinoma. Gynecol Oncol. 2018. PMID: 30551884. doi:10.1016/j.ygyno.2018.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。